Fidelis Capital Partners LLC Raises Stake in Pfizer Inc. (NYSE:PFE)

Fidelis Capital Partners LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 5.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,835 shares of the biopharmaceutical company’s stock after buying an additional 1,267 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Pfizer were worth $746,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in PFE. Cornerstone Wealth Management LLC grew its holdings in Pfizer by 19.4% in the 1st quarter. Cornerstone Wealth Management LLC now owns 63,545 shares of the biopharmaceutical company’s stock valued at $1,763,000 after buying an additional 10,314 shares in the last quarter. First Trust Direct Indexing L.P. grew its holdings in shares of Pfizer by 45.0% during the 1st quarter. First Trust Direct Indexing L.P. now owns 51,735 shares of the biopharmaceutical company’s stock worth $1,436,000 after purchasing an additional 16,060 shares during the period. Accel Wealth Management purchased a new position in shares of Pfizer during the 1st quarter worth $205,000. American National Bank & Trust Co. VA purchased a new position in shares of Pfizer during the 1st quarter worth $285,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Pfizer during the 1st quarter worth $315,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

PFE stock opened at $28.52 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The firm has a market capitalization of $161.61 billion, a P/E ratio of 38.54, a P/E/G ratio of 0.99 and a beta of 0.67. The business’s 50-day moving average is $29.06 and its two-hundred day moving average is $28.56. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.17) EPS. Analysts anticipate that Pfizer Inc. will post 2.67 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.89%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. UBS Group increased their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. Finally, Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.